| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | Alpelisib/BYL-719 |
| CAS No. | 1217486-61-7 |
| Molecular formula | C19H22F3N5O2S |
| Molecular weight | 441.47 |
| Purity | 99% |
| Appearance | White or almost white powder |
| Package | Aluminum Bag;Drums |
| Shelf life | 2 years |
Alpelisib is used for advanced solid tumours. Alpelisib shows statistically significant dose-dependent anti-tumor efficacy in PIK3CA mutant xenograft models in rodents. BYL719 has a low clearance, a half-life of 8.5 h and its exposure increases dose proportionally between 30mg/d and 450mg/d, displaying a low inter-individual variability in Cmax and AUC in human. BYL719(270mg/d) shows first signs of clinical efficacy include 1 confirmed partial response in a patient with ER+ breast cancer, and significant PET responses (PMR) and/or tumor shrinkage are achieved in 8 out of 17 evaluated patients.
){kind=link}